Antimicrobial Agents and Novel Vaccines
Vaccines can reduce the prevalence of resistance by reducing the need for antimicrobial use and can reduce its impact by reducing the total number of cases. By reducing the number of pathogens that may be responsible for a particular clinical syndrome, vaccines can permit the use of narrower-spectrum antibiotics for empirical therapy. These effects may be amplified by herd immunity, extending protection to unvaccinated persons in the population. Because much selection for resistance is due to selection on bystander members of the normal flora, vaccination can reduce pressure for resistance even in pathogens not included in the vaccine. Some vaccines have had disproportionate effects on drug-resistant lineages within the target species, a benefit that could be more deliberately exploited in vaccine design.
- Hib conjugate vaccine
- Respiratory virus vaccine
Related Conference of Antimicrobial Agents and Novel Vaccines
5th International Conference on Microbiology and Infectious Diseases
11th International Conference on Infectious and Rare Diseases
13th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs
20th World Conference on Infectious Diseases, Prevention and Control
8th Annual Congress on Bacterial, Viral and Infectious Diseases
13th International Conference on Infectious Diseases, Bacteriology and Antibiotics
Antimicrobial Agents and Novel Vaccines Conference Speakers
Recommended Sessions
- Antibiotic Resistance Leads to Increased Mortality
- Antibiotic Therapy and Antimicrobial Drugs
- Antimicrobial Agents and Chemotherapy
- Antimicrobial Agents and Novel Vaccines
- Antimicrobial Agents in Clinical Treatment
- Antimicrobial Pathogens : Alternative Approaches
- Antimicrobial Textiles Market
- Antimicrobial Therapy for Gum Disease
- Antimicrobiology in Epidemiology
- Community Acquired Antimicrobial Resistance: Is It Controllable?
- Global Antibacterial Drugs Market Key
- Infection Diseases and Agents
- Molecular Epidemiology of Neoplastic and Non-neoplastic disease
- Neuroinfectious Diseases
- Pediatric Infectious Disease
- Pharmalogical Consideration of Infectious Disease and Agents
- Plant Based Vaccines
- Veterinary Pathology and Infectious Diseases
Related Journals
Are you interested in
- 1.Infectious Diseases and Neuro Infectious Diseases - Infectious Diseases_2025 (Canada)
- 10. HIV/AIDS - Infectious Diseases_2025 (Canada)
- 11. Pediatric Infectious Diseases/ Childhood Infectious Diseases - Infectious Diseases_2025 (Canada)
- 12. Respiratory Diseases - Infectious Diseases_2025 (Canada)
- 13. Sexually Transmitted Diseases/ Sexually Transmitted Infections - Infectious Diseases_2025 (Canada)
- 14. Viral Infectious Diseases - Infectious Diseases_2025 (Canada)
- 15. Malaria and Hepatitis - Infectious Diseases_2025 (Canada)
- 16. Immunology of Infections - Infectious Diseases_2025 (Canada)
- 17. Vaccines and Vaccination - Infectious Diseases_2025 (Canada)
- 18. Tuberculosis - Infectious Diseases_2025 (Canada)
- 19. New Antiviral, Antibacterial and Antifungal Agents - Infectious Diseases_2025 (Canada)
- 2. Coronavirus(nCOV) - Infectious Diseases_2025 (Canada)
- 20. Nosocomial Infections - Infectious Diseases_2025 (Canada)
- 21. Parasitic Diseases - Infectious Diseases_2025 (Canada)
- 22. Surgical Site Infections - Infectious Diseases_2025 (Canada)
- 3. Infectious Diseases Prevention, Control and Cure - Infectious Diseases_2025 (Canada)
- 4. Bacterial & Fungal Infectious Diseases - Infectious Diseases_2025 (Canada)
- 5. Rare Infectious Diseases and Immune Deficiencies - Infectious Diseases_2025 (Canada)
- 6. Rare Diseases in Cancer and Aging - Infectious Diseases_2025 (Canada)
- 7. Global Trends in Emerging Infectious Diseases - Infectious Diseases_2025 (Canada)
- 8. Ebola and Zika Viral Infections - Infectious Diseases_2025 (Canada)
- 9. Clinical Research and Public Awareness - Infectious Diseases_2025 (Canada)
- A prospective study of dermatological infections - Emerging Infectious Diseases 2025 (Canada)
- Alcohol and Drug Use - STD-HIV AIDS-2025 (USA)
- Antimicrobial Resistance - Emerging Infectious Diseases 2025 (Canada)
- Antimicrobial Stewardship/Antimicrobial Resistance - Infection Prevention 2025 (UK)
- Bacterial, Parasitic and Fungal Infections - Infection Prevention 2025 (UK)
- Blood Borne Infections/Sepsis/Septicaemia - Infection Prevention 2025 (UK)
- Cardiovascular Diseases and Disorders - Emerging Infectious Diseases 2025 (Canada)
- Causes and Symptoms of Infections - Infection Prevention 2025 (UK)
- Changing Patterns of Infectious Diseases - Emerging Infectious Diseases 2025 (Canada)
- Clinical Research and Case Reports - STD-HIV AIDS-2025 (USA)
- Co-infections Associated with STDs - STD-HIV AIDS-2025 (USA)
- Covid_19 Infections - Infection Prevention 2025 (UK)
- Dental diseases & Infections - Emerging Infectious Diseases 2025 (Canada)
- Diabetes and Wound Care - Emerging Infectious Diseases 2025 (Canada)
- Diagnosis and Treatment - STD-HIV AIDS-2025 (USA)
- Diagnosis of infectious Diseases - Infection Prevention 2025 (UK)
- Diagnostics and Laboratory Techniques - Emerging Infectious Diseases 2025 (Canada)
- Emerging and Re-Emerging Infections - Infection Prevention 2025 (UK)
- Epidemiology - Infection Prevention 2025 (UK)
- Epidemiology and Surveillance - Emerging Infectious Diseases 2025 (Canada)
- Gastrointestinal and Urinary Tract Infections - Infection Prevention 2025 (UK)
- Global Climatic Change and Emerging Infectious Diseases - Emerging Infectious Diseases 2025 (Canada)
- Global Health Security - Emerging Infectious Diseases 2025 (Canada)
- Global hotspots and correlates of emerging zoonotic diseases - Emerging Infectious Diseases 2025 (Canada)
- Global Trends in Emerging Infections - Infection Prevention 2025 (UK)
- Hepatitis Prevention - Infection Prevention 2025 (UK)
- HIV and Women's Health Issues - STD-HIV AIDS-2025 (USA)
- Human Monkeypox: An Emerging Zoonosis - Emerging Infectious Diseases 2025 (Canada)
- Immunizations and Vaccination - Infection Prevention 2025 (UK)
- Infection Control in Critical Care - Infection Prevention 2025 (UK)
- Infection Control Procedures - Infection Prevention 2025 (UK)
- Infection Prevention and Control - Infection Prevention 2025 (UK)
- Neuro Infections - Infection Prevention 2025 (UK)
- Nosocomial Infections and Control - Infection Prevention 2025 (UK)
- Nosocomial Infections and Their Control Strategies - Emerging Infectious Diseases 2025 (Canada)
- Outbreak Investigation and Response - Emerging Infectious Diseases 2025 (Canada)
- Pediatric HIV - STD-HIV AIDS-2025 (USA)
- Pediatric Infectious Diseases - Emerging Infectious Diseases 2025 (Canada)
- Perspectives on Gastrointestinal Infections - Emerging Infectious Diseases 2025 (Canada)
- Plants Diseases and Infection Control - Infection Prevention 2025 (UK)
- Public Health - STD-HIV AIDS-2025 (USA)
- Public Health Policy and Preparedness - Emerging Infectious Diseases 2025 (Canada)
- Recent Advancements - STD-HIV AIDS-2025 (USA)
- Respiratory Infectious Diseases and Therapy - Infection Prevention 2025 (UK)
- SARS and MERS: Recent Insights into Emerging Coronaviruses - Emerging Infectious Diseases 2025 (Canada)
- Sexual Health - STD-HIV AIDS-2025 (USA)
- Sexually Transmitted Diseases - STD-HIV AIDS-2025 (USA)
- Testing and Health Monitoring - STD-HIV AIDS-2025 (USA)
- The Science of SARS-CoV-2 - Emerging Infectious Diseases 2025 (Canada)
- Therapeutics and Treatment Strategies - Emerging Infectious Diseases 2025 (Canada)
- Transmission and Prevention - STD-HIV AIDS-2025 (USA)
- Vaccines and Immunization - Emerging Infectious Diseases 2025 (Canada)
- Vaccines and People with HIV - STD-HIV AIDS-2025 (USA)
- Vector-borne diseases: New Approaches to Control Vector from disease transmission - Emerging Infectious Diseases 2025 (Canada)
- Viral Infections and Recent Advancements - Infection Prevention 2025 (UK)